Abbott Laboratories Stock News

Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.

Their products are indispensible, and their continued growth is nearly guaranteed.

The next crash is always around the corner, so get ready.

Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Europe Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering.

Abbott Laboratories (NYSE:ABT) had its price target lowered by Raymond James from $150.00 to $134.00 in a research note released on Thursday. ABT has been the topic of several other research reports. Morgan Stanley upped their price objective on Abbott Laboratories from $136.00 to $146.00 and gave the company an overweight rating in a research []

Another factual information on the "Immunoprotein Diagnostic Testing Market" has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various perspectives, for example, global market patterns, pieces of the

Abbott Laboratories (ABT) shares closed today at 0.1% below its 52 week high of $139.27, giving the company a market cap of $245B. The stock is currently up 28.9% year-to-date, up 30.3% over the past 12 months, and up 296.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 13.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 68.0% The company's stock price performance over the past 12 months beats the peer average by 55.8% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 9.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

TFC Financial Management lifted its position in Abbott Laboratories (NYSE:ABT) by 39.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 9,038 shares of the healthcare product makers stock after acquiring an additional 2,578 shares during the period. Abbott Laboratories comprises about 0.4% of TFC Financial Managements investment portfolio, making the stock its 26th []

Redhawk Wealth Advisors Inc. lessened its position in shares of Abbott Laboratories (NYSE:ABT) by 58.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,852 shares of the healthcare product makers stock after selling 5,312 shares during the period. Redhawk Wealth Advisors Inc.s holdings []

DUBLIN--(BUSINESS WIRE)--The "Dengue Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)" report has been added to ResearchAndMarkets.com''s offering. The global dengue testing market was valued at USD 455.77 million in 2020 and is expected to reach USD 597.78 million by 2026, registering a CAGR of 4.74% during the forecast period. Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages. So, most of the people are confusing it to

Abbott Laboratories (NYSE:ABT) had its target price increased by Raymond James from $134.00 to $150.00 in a research report sent to investors on Wednesday morning, Stock Target Advisor reports. They currently have an outperform rating on the healthcare product makers stock. A number of other analysts have also recently weighed in on the company. SVB [] The post Abbott Laboratories (NYSE:ABT) Price Target Raised to $150.00 appeared first on ETF Daily News .

Abbott Laboratories (ABT) shares closed today at 0.2% below its 52 week high of $139.27, giving the company a market cap of $239B. The stock is currently up 25.5% year-to-date, up 27.1% over the past 12 months, and up 286.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 rose 0.3%. Trading Activity Trading volume this week was 21.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 59.6% The company's stock price performance over the past 12 months beats the peer average by 56.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 8.1% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

America First Investment Advisors LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 144,199 shares of the healthcare product makers stock after selling 1,932 shares during the period. Abbott Laboratories accounts for about 5.2% of America []

Dumont & Blake Investment Advisors LLC trimmed its stake in Abbott Laboratories (NYSE:ABT) by 0.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,017 shares of the healthcare product makers stock after selling 93 shares during the quarter. Dumont & Blake Investment Advisors LLCs []